DK0832207T3 - Fremgangsmåde til identifikation af biologisk aktive peptider og nukleinsyrer - Google Patents

Fremgangsmåde til identifikation af biologisk aktive peptider og nukleinsyrer

Info

Publication number
DK0832207T3
DK0832207T3 DK96916019T DK96916019T DK0832207T3 DK 0832207 T3 DK0832207 T3 DK 0832207T3 DK 96916019 T DK96916019 T DK 96916019T DK 96916019 T DK96916019 T DK 96916019T DK 0832207 T3 DK0832207 T3 DK 0832207T3
Authority
DK
Denmark
Prior art keywords
cells
changed
biologically active
nucleic acids
sequences
Prior art date
Application number
DK96916019T
Other languages
Danish (da)
English (en)
Inventor
Martin Roland Jensen
Finn Skou Pedersen
Soeren Mouritsen
Peter Hindersson
Mogens Duch
Michael Schandorf Soerensen
Iben Dalum
Anders Henrik Lund
Original Assignee
M & E Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8095753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0832207(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by M & E Biotech As filed Critical M & E Biotech As
Application granted granted Critical
Publication of DK0832207T3 publication Critical patent/DK0832207T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96916019T 1995-06-02 1996-05-31 Fremgangsmåde til identifikation af biologisk aktive peptider og nukleinsyrer DK0832207T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK62995 1995-06-02
PCT/DK1996/000231 WO1996038553A1 (fr) 1995-06-02 1996-05-31 Procede d'identification de peptides et d'acides nucleiques biologiquement actifs

Publications (1)

Publication Number Publication Date
DK0832207T3 true DK0832207T3 (da) 2000-11-06

Family

ID=8095753

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96916019T DK0832207T3 (da) 1995-06-02 1996-05-31 Fremgangsmåde til identifikation af biologisk aktive peptider og nukleinsyrer

Country Status (12)

Country Link
EP (2) EP1041143A3 (fr)
JP (1) JPH11505724A (fr)
KR (1) KR19990022157A (fr)
AT (1) ATE196312T1 (fr)
AU (1) AU699568B2 (fr)
CA (1) CA2222879A1 (fr)
DE (1) DE69610310T2 (fr)
DK (1) DK0832207T3 (fr)
ES (1) ES2151167T3 (fr)
GR (1) GR3035017T3 (fr)
PT (1) PT832207E (fr)
WO (1) WO1996038553A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0877752T3 (da) 1996-01-23 2003-09-15 Univ Leland Stanford Junior Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
AU777489B2 (en) * 1996-01-23 2004-10-21 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6969584B2 (en) 1997-06-12 2005-11-29 Rigel Pharmaceuticals, Inc. Combinatorial enzymatic complexes
US6700040B2 (en) * 1998-01-16 2004-03-02 Large Scale Biology Corporation Cytoplasmic gene inhibition or gene expression in transfected plants by a tobraviral vector
WO1999041371A1 (fr) * 1998-02-13 1999-08-19 Genetrace Systems, Inc. Utilisation de ribozymes afin d'identifier la fonction de genes
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
US7005423B1 (en) 1999-07-02 2006-02-28 Devgen Nv Characterization of gene function using double stranded RNA inhibition
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
NZ509013A (en) * 1998-07-20 2002-12-20 Inoxell As Novel methods for the identification of ligand and target biomolecules
EP1270746A1 (fr) * 1998-07-20 2003-01-02 Inoxell A/S Methods pour l'identification de ligands et de biomolecules cibles
WO2000014216A1 (fr) * 1998-09-04 2000-03-16 Zk Pharmaceuticals, Inc. Technique de selection des peptides inhibant la liaison d'une proteine virale de surface a un recepteur de surface cellulaire
DE69918260T2 (de) * 1999-03-29 2005-07-14 Michael Blind Methoden zur Identifizierung und Validierung von funktionellen Zielen mittels Intrameren oder in vivo Selektion
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2002068630A1 (fr) * 2001-02-22 2002-09-06 Praecis Pharmaceuticals Incorporated Procedes d'identification de peptides modulant un processus biologique
IL142481A0 (en) * 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
US20040142379A1 (en) 2003-01-16 2004-07-22 Carlsberg Research Laboratory Affinity fishing for ligands and proteins receptors
EP2098536A1 (fr) * 2008-03-05 2009-09-09 4-Antibody AG Isolation et identification de protéines de liaison spécifiques à des antigènes ou à des ligands
WO2016138231A2 (fr) 2015-02-27 2016-09-01 Sauder Timothy Lee Commutateur bi-stable moléculaire à code à barres
US10620185B2 (en) 2015-02-27 2020-04-14 Aptascan, Inc. Molecular barcoded bi-stable switch
US11739370B1 (en) 2020-01-10 2023-08-29 Gordian Biotechnology, Inc. Methods and compositions for in vivo screening of therapeutics through spatial transcriptomics
US20240301586A1 (en) * 2021-01-19 2024-09-12 Hope Patents, Llc A method for identifying peptide therapeutics to treat a variety of conditions
EP4330406A4 (fr) * 2021-04-26 2025-03-05 Gordian Biotechnology, Inc. Compositions et procédés pour le criblage invivo de produits thérapeutiques utilisant le séquençage mononucléaire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (fr) * 1988-09-02 1997-04-02 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
DE4002897A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
ATE213779T1 (de) * 1991-08-07 2002-03-15 W French Anderson Interne ribosom eintrittsstellen enthaltene retrovirale vektoren
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
AU6132994A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69434860T2 (de) * 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
CA2157931A1 (fr) * 1993-03-12 1994-09-15 Clague P. Hodgson Vecteurs ameliores pour la therapie genique
WO1995004824A1 (fr) * 1993-08-05 1995-02-16 Medvet Science Pty. Ltd. Production de banques d'adn et vecteurs retroviraux utilises a cet effet
WO1995011998A1 (fr) * 1993-10-26 1995-05-04 United Biomedical, Inc. Bibliotheques structurees d'antigenes de synthese utilisables a des fins de diagnostic, de vaccin et de therapie

Also Published As

Publication number Publication date
AU699568B2 (en) 1998-12-10
CA2222879A1 (fr) 1996-12-05
EP0832207A1 (fr) 1998-04-01
KR19990022157A (ko) 1999-03-25
GR3035017T3 (en) 2001-03-30
WO1996038553A1 (fr) 1996-12-05
EP1041143A3 (fr) 2000-11-29
JPH11505724A (ja) 1999-05-25
ES2151167T3 (es) 2000-12-16
DE69610310T2 (de) 2001-03-15
EP0832207B1 (fr) 2000-09-13
ATE196312T1 (de) 2000-09-15
DE69610310D1 (de) 2000-10-19
AU5893396A (en) 1996-12-18
EP1041143A2 (fr) 2000-10-04
PT832207E (pt) 2001-03-30

Similar Documents

Publication Publication Date Title
DK0832207T3 (da) Fremgangsmåde til identifikation af biologisk aktive peptider og nukleinsyrer
Fisch et al. A strategy of exon shuffling for making large peptide repertoires displayed on filamentous bacteriophage.
Gilbert The exon theory of genes
Pavia et al. The generation of molecular diversity
ES2124224T3 (es) Metodo para escrutar genotecas recombinantes.
NO885659L (no) Mycobakterielle rekombinanter og peptider.
DE69434578D1 (de) Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren
EP1798239A3 (fr) Récepteurs de protéine G-couplés et utilisations correspondantes
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
ATE283359T1 (de) Methode zum durchforsten von banken mittels chimären bindungspetiden
Martinez et al. Mutational analysis and secondary structure model of the RNP1-like sequence motif of transcription termination factor Rho
WO1996017941A3 (fr) Production de peptides amides a l'extremite c-terminale a partir de produits de recombinaison proteiques
DE69831338D1 (de) Verbesserter klonierungsvektor mit markerinaktivierungssystem
ATE498013T1 (de) Für zellzyklusproteine kodierende nukleinsäure und deren verwendung
AU8110487A (en) DNA molecules coding for proteins targeted to plant cell walls
BR0016432A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, descendentes, sementes ou material celular reproduzìvel, método de produção de um ou mais polipeptìdeo(s), tcmrp isolada, polipeptìdeo isolado, anticorpo, kit de teste, método para produzir um produto quìmico fino, produto quìmico fino, e, uso de um produto quìmico fino ou de polipeptìdeo(s).
WO2000039149A3 (fr) Proteines secretees et leurs utilisations
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
US20030082514A1 (en) Method for identification of biologically active peptides and nucleic acids
Mössner et al. Directed evolution with fast and efficient selection technologies
CA2256125A1 (fr) Gene chimere forme de sequences d'adn codant pour les sites antigeniques de quatre proteines de l. infantum, utile pour le diagnostic serologique de la leishmaniose canine, et proteine obtenue
WO2002053589A3 (fr) Molecules d'acides nucleiques codant des interacteurs dim et utilisations
Thomas et al. Towards random polypeptide synthesis
WO2000032746A3 (fr) Acides nucleiques et polypeptides netrinoïdes et ependyminoïdes et leurs utilisations
PT1143006E (pt) Sequências de adn/vectores de bibliotecas de anticorpos combinatórios humanos